Palisade Bio rises; bowel disease drug set for global conference spotlight

Palisade Bio

16/01/2026 14:20

** Shares of drug developer Palisade Bio PALI.O rise 1.7% to $1.78 premarket

** Co says its experimental ulcerative colitis drug, PALI‑2108, is set to be featured at two major medical conferences next year

** Ulcerative colitis is a chronic bowel disease that causes inflammation and bleeding in the colon

** PALI says early‑stage data shows all patients responded with no serious safety issues

** Presentations are planned for the Crohn’s & Colitis Congress in Las Vegas and the European Crohn’s and Colitis Organisation Congress in Stockholm - PALI

** Says it is preparing a larger 12‑week study and planning Crohn’s disease research

** As of last close, stock up ~42% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))